DPP4 and obesity due to melanocortin 4 receptor deficiency: An analysis of subjects with type 2 diabetes and obesity in the LYDIA trial found there was no significant difference in the effects of liraglutide on hsCRP compared with the dipeptidyl peptidase-4 inhibitor sitagliptin [33].